O'Brien Institute, Melbourne, Victoria, Australia.
Tissue Eng Part A. 2012 Nov;18(21-22):2210-9. doi: 10.1089/ten.TEA.2011.0719. Epub 2012 Jul 11.
Ischemic preconditioning (IPC) is a potent and effective means of protecting cells against ischemic injury. The protection has been demonstrated to involve release of paracrine factors that promote cell survival and angiogenesis, factors important for successful tissue engineering. The aim of the present study was to determine whether IPC of a vascular bed in vivo is an effective strategy to prepare it for tissue engineering with implanted cells. To test this hypothesis, an in vivo vascularized tissue engineering approach was employed, whereby polyacrylic chambers were placed around the femoral vessels of adult Sprague-Dawley rats. IPC was induced by 3 cycles of 5 min femoral artery occlusion interspersed with 5-min periods of reperfusion. Rats subjected to IPC generated bigger tissue constructs at 7 and 28 days postimplantation of empty chambers (∼50% increase in weight and volume, p<0.05). Morphometric counting of Masson trichrome stained tissue sections revealed significantly greater tissue construct volumes in ischemic preconditioned vascular beds at 7 and 28 days, increasing both fibrin matrix and vascularized tissue. Furthermore, morphometry of lectin-labeled blood vessels indicated an increase in vascular volume in IPC tissue constructs (∼100% increase vs. control, p<0.05). To investigate the cytoprotective effect of IPC, we implanted DiI-labeled neonatal rat cardiomyocytes in the chambers for 3 days, and IPC significantly reduced apoptosis of implanted cells as determined by the TUNEL assay and cleaved caspase-3 immunostaining. Furthermore, IPC significantly increased the cardiac muscle volume and vascular volume at 28 days after implantation of cardiomyocytes. In conclusion, in vivo IPC promotes survival of implanted cardiomyocytes and is associated with enhanced angiogenesis. IPC may represent a new approach to optimize tissue engineering with implanted cells.
缺血预处理(IPC)是一种保护细胞免受缺血性损伤的有效方法。已经证明这种保护涉及到释放旁分泌因子,促进细胞存活和血管生成,这些因子对成功的组织工程很重要。本研究的目的是确定体内血管床的 IPC 是否是一种有效的策略,以便用植入细胞为其进行组织工程准备。为了验证这一假设,采用了一种体内血管化组织工程方法,即将聚甲基丙烯酸甲酯(PMMA)室放置在成年 Sprague-Dawley 大鼠的股血管周围。IPC 通过 3 个 5 分钟的股动脉闭塞周期和 5 分钟的再灌注周期来诱导。与植入空室的大鼠相比,接受 IPC 的大鼠在植入后 7 和 28 天产生了更大的组织构建体(重量和体积增加约 50%,p<0.05)。Masson 三色染色组织切片的形态计量计数显示,在缺血预处理的血管床中,组织构建体的体积在 7 和 28 天均显著增加,增加了纤维蛋白基质和血管化组织。此外,用凝集素标记的血管的形态计量学表明,IPC 组织构建体中的血管体积增加(与对照相比增加约 100%,p<0.05)。为了研究 IPC 的细胞保护作用,我们将 DiI 标记的新生大鼠心肌细胞植入室中 3 天,通过 TUNEL 检测和 cleaved caspase-3 免疫染色,IPC 显著减少了植入细胞的凋亡。此外,IPC 显著增加了植入心肌细胞 28 天后的心肌和血管体积。总之,体内 IPC 促进了植入的心肌细胞的存活,并与增强的血管生成有关。IPC 可能代表了一种优化植入细胞组织工程的新方法。